Jaewon Oh

Jaewon Oh

Auto-generated profile, based on publicly available information

Jaewon Oh

Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in ACS Nano
Verified
Journal Article
Closed access
JPJooyeon Park
Jooyeon Park
BKBokyoung Kim
Bokyoung Kim
JHJin Han
Jin Han
JOJaewon Oh
Jaewon Oh
SPSubeom Park
Subeom Park
BKByung-Soo Kim
Byung-Soo Kim

31 March 2011 in Clinical Biochemistry
Verified
Journal Article
Closed access
SKSeok-Min Kang
Seok-Min Kang
JPJong-Chul Park
Jong-Chul Park
MSMin-Jeong Shin
Min-Jeong Shin
HLHyeran Lee
Hyeran Lee
JOJaewon Oh
Jaewon Oh
JCJi Hyung Chung
Ji Hyung Chung

1 January 2020 in Korean Circulation Journal
Verified
Journal Article
Open access
PDF file
SLSeul-Gee Lee
Seul-Gee Lee
JLJun-Won Lee
Jun-Won Lee
JLJung-Jae Lee
Jung-Jae Lee
Jung Sun KimJung Sun Kim
Jung Sun Kim
OLOh-Hyun Lee
Oh-Hyun Lee
YJYangsoo Jang
Yangsoo Jang
Korean Circulation Journal 대한심장학회지 순환기 Lee SG, et al. Korean Circ J. 2019 Aug;50:e53. https://doi.org/10.4070/kcj.2019.0296

1 April 2005 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
HSHye-Jin Shin
Hye-Jin Shin
JOJaewon Oh
Jaewon Oh
SKSeok Min Kang
Seok Min Kang
JLJong Ho Lee
Jong Ho Lee
MSMin-Jeong Shin
Min-Jeong Shin
JCJi Hyung Chung
Ji Hyung Chung

1 August 2009 in Journal of Cardiac Failure
Verified
Journal Article
Closed access
JOJaewon Oh
Jaewon Oh
SKSeok-Min Kang
Seok-Min Kang
NHNamki Hong
Namki Hong
JCJi-Won Choi
Ji-Won Choi
SLSang-Hak Lee
Sang-Hak Lee
NCNamsik Chung
Namsik Chung

13 August 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BLBeom Seob Lee
Beom Seob Lee
JOJaewon Oh
Jaewon Oh
SKSung Ku Kang
Sung Ku Kang
SPSungha Park
Sungha Park
SLSang-Hak Lee
Sang-Hak Lee
SKSeok-Min Kang
Seok-Min Kang
Insulin inhibits ischemia/reperfusion-induced myocardial apoptosis through the PI3K/Akt/mTOR pathway. Survivin is a key regulator of anti-apoptosis against doxorubicin-induced cardiotoxicity. Insulin increases survivin expression in cardiac myocytes to mediate cytoprotection. However, the mechanism by which survivin mediates the protective effect of insulin against doxorubicin-associated injury remains to be determined. In this study, we demonstrated that pretreatment of H9c2 cardiac myocytes with insulin resulted in a significant decrease in doxorubicin-induced apoptotic cell death by reducing cytochrome c release and caspase-3 activation. Doxorubicin-induced reduction of survivin mRNA and protein levels was also significantly perturbed by insulin pretreatment. Reducing survivin expression with survivin siRNA abrogated insulin-mediated inhibition of caspase-3 activation, suggesting that insulin signals to survivin inhibited caspase-3 activation. Interestingly, pretreatment of H9c2 cells with insulin or MG132, a proteasome inhibitor, inhibited doxorubicin-induced degradation of the transcription factor Sp1. ChIP assay showed that pretreatment with insulin inhibited doxorubicin-stimulated Sp1 dissociation from the survivin promoter. Finally using pharmacological inhibitors of the PI3K pathway, we showed that insulin-mediated activation of the PI3K/Akt/mTORC1 pathway prevented doxorubicin-induced proteasome-mediated degradation of Sp1. Taken together, insulin pretreatment confers a protective effect against doxorubicin-induced cardiotoxicity by promoting Sp1-mediated transactivation of survivin to inhibit apoptosis. Our study is the first to define a role for survivin in cellular protection by insulin against doxorubicin-associated injury and show that Sp1 is a critical factor in the transcriptional regulation of survivin.